Public Employees Retirement System of Ohio Has $2.69 Million Holdings in DexCom, Inc. (DXCM)

Public Employees Retirement System of Ohio decreased its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 43.2% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 36,814 shares of the medical device company’s stock after selling 27,987 shares during the period. Public Employees Retirement System of Ohio’s holdings in DexCom were worth $2,693,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. FMR LLC lifted its stake in DexCom by 9.9% during the second quarter. FMR LLC now owns 10,824,306 shares of the medical device company’s stock worth $791,799,000 after purchasing an additional 978,898 shares during the period. Janus Henderson Group PLC lifted its stake in DexCom by 101,699.8% during the second quarter. Janus Henderson Group PLC now owns 6,828,731 shares of the medical device company’s stock worth $499,522,000 after purchasing an additional 6,822,023 shares during the period. Vanguard Group Inc. lifted its stake in DexCom by 3.4% during the second quarter. Vanguard Group Inc. now owns 6,821,102 shares of the medical device company’s stock worth $498,963,000 after purchasing an additional 224,808 shares during the period. BlackRock Inc. lifted its stake in DexCom by 5.5% during the second quarter. BlackRock Inc. now owns 4,391,404 shares of the medical device company’s stock worth $321,232,000 after purchasing an additional 230,542 shares during the period. Finally, Ameriprise Financial Inc. lifted its stake in DexCom by 18.2% during the second quarter. Ameriprise Financial Inc. now owns 3,948,468 shares of the medical device company’s stock worth $288,669,000 after purchasing an additional 607,972 shares during the period.

A number of brokerages have commented on DXCM. Canaccord Genuity restated a “buy” rating and set a $90.00 price target on shares of DexCom in a research note on Tuesday, August 22nd. ValuEngine upgraded shares of DexCom from a “sell” rating to a “hold” rating in a research note on Friday, September 1st. BidaskClub upgraded shares of DexCom from a “sell” rating to a “hold” rating in a research note on Saturday, August 19th. Barclays PLC initiated coverage on shares of DexCom in a research note on Friday, September 15th. They issued an “equal weight” rating and a $76.00 target price for the company. Finally, Cowen and Company reiterated a “buy” rating and issued a $90.00 target price on shares of DexCom in a research note on Friday, July 14th. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating and fourteen have issued a buy rating to the company. DexCom presently has an average rating of “Buy” and an average target price of $72.19.

In other news, EVP Richard Doubleday sold 1,635 shares of the firm’s stock in a transaction on Monday, October 23rd. The shares were sold at an average price of $44.82, for a total transaction of $73,280.70. Following the completion of the transaction, the executive vice president now owns 65,049 shares of the company’s stock, valued at $2,915,496.18. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Kevin R. Sayer sold 6,000 shares of the firm’s stock in a transaction on Friday, August 11th. The shares were sold at an average price of $69.77, for a total transaction of $418,620.00. The disclosure for this sale can be found here. In the last three months, insiders sold 23,208 shares of company stock valued at $1,597,567. 1.70% of the stock is owned by insiders.

DexCom, Inc. (NASDAQ DXCM) opened at 44.97 on Wednesday. The company’s market cap is $3.89 billion. The company has a 50-day moving average of $54.18 and a 200 day moving average of $67.68. DexCom, Inc. has a 52-week low of $42.62 and a 52-week high of $88.80.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings data on Tuesday, August 1st. The medical device company reported ($0.16) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.23) by $0.07. The business had revenue of $170.60 million during the quarter, compared to the consensus estimate of $166.54 million. DexCom had a negative net margin of 10.27% and a negative return on equity of 27.90%. The firm’s revenue was up 24.3% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.24) EPS. Equities research analysts predict that DexCom, Inc. will post ($0.80) EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “Public Employees Retirement System of Ohio Has $2.69 Million Holdings in DexCom, Inc. (DXCM)” was originally posted by Community Financial News and is the sole property of of Community Financial News. If you are accessing this story on another website, it was stolen and reposted in violation of United States & international copyright & trademark legislation. The correct version of this story can be read at https://www.com-unik.info/2017/11/01/public-employees-retirement-system-of-ohio-has-2-69-million-holdings-in-dexcom-inc-dxcm.html.

DexCom Company Profile

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.

Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM).

Institutional Ownership by Quarter for DexCom (NASDAQ:DXCM)

What are top analysts saying about DexCom Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for DexCom Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit